5 Key Takeaways

• 1

  Elevated blood levels of phosphorylated tau are found in patients with AL and ATTR amyloidosis, suggesting its potential as a diagnostic biomarker.

• 2

  The study analyzed serum samples from 280 individuals, demonstrating higher p-tau181 levels in amyloidosis patients compared to controls.

• 3

  P-tau181 showed moderate diagnostic discrimination with an area under the curve of 0.82, indicating its effectiveness in identifying amyloidosis.

• 4

  Patients with amyloidosis-related neuropathy had higher p-tau181 levels, differentiating them from individuals with neuropathy from other causes.

• 5

  The findings suggest phosphorylated tau may reflect cellular responses to amyloid deposition, warranting further research for diagnostic integration.